Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Up 4.2% – Here’s What Happened

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) rose 4.2% during trading on Friday . The company traded as high as $0.9973 and last traded at $0.99. Approximately 126,338 shares were traded during trading, a decline of 17% from the average session volume of 151,972 shares. The stock had previously closed at $0.95.

Analyst Ratings Changes

Separately, Stephens reaffirmed an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Actinium Pharmaceuticals has an average rating of “Buy” and a consensus price target of $5.00.

Actinium Pharmaceuticals Stock Up 4.2%

The firm has a market cap of $31.06 million, a price-to-earnings ratio of -0.71 and a beta of -0.06. The company has a 50 day moving average of $1.17 and a 200 day moving average of $1.22.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ATNM. Goldman Sachs Group Inc. bought a new stake in shares of Actinium Pharmaceuticals in the fourth quarter worth $96,000. Two Sigma Investments LP boosted its stake in Actinium Pharmaceuticals by 403.4% during the 3rd quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock valued at $375,000 after acquiring an additional 187,748 shares during the last quarter. Vanguard Group Inc. boosted its stake in Actinium Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after acquiring an additional 12,703 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Actinium Pharmaceuticals in the 2nd quarter worth about $306,000. Finally, Marshall Wace LLP bought a new stake in shares of Actinium Pharmaceuticals in the 2nd quarter worth about $137,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.